Emerald Advisers’s Praxis Precision Medicines PRAX Stock Holding History

Emerald Advisers’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$32.3M	Buy	+110,764	New	+$36.7M	0.89%	47

Other funds holding PRAX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

SEB Asset Management Stockholm $27B AUM

Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return

Emerald Advisers's PRAX Position: Q3 2026 in Review

Emerald Advisers opened a new position in Praxis Precision Medicines (PRAX) in Q3 2026: 110,764 shares worth $32.3M. The stake represents 0.89% of the portfolio and ranks #47 among its holdings.

123 funds tracked by Wall St. Rank hold PRAX as of Q3 2026.

Emerald Advisers held 110,764 shares of Praxis Precision Medicines worth $32.3M as of Q3 2026.
Praxis Precision Medicines was a new Emerald Advisers position in Q3 2026.
Praxis Precision Medicines made up 0.89% of Emerald Advisers's portfolio in Q3 2026, its #47 holding.
123 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q3 2026.

Based on Emerald Advisers's 13F filing for Q3 2026, filed 9 Nov 2026.